Auron Therapeutics
Biotechnology company with a recent SEC Form D offering.
Biotechnology company headquartered in Wellesley, MASSACHUSETTS. Filed SEC Form D on 20260813 for a $7.1M Regulation D offering.
Biotech
📍 Wellesley, MASSACHUSETTS
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Auron Therapeutics going public?
No. Auron Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Auron Therapeutics' valuation in 2026?
No confirmed valuation is on record for Auron Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Auron Therapeutics filed an S-1?
No public S-1 is on file for Auron Therapeutics.
How much has Auron Therapeutics raised?
Auron Therapeutics has raised $7.12M in total, most recently a Form D filing of $7.12M in 20260813.
Is Auron Therapeutics publicly traded — can you buy Auron Therapeutics stock?
No. Auron Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Auron Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
HQ
Wellesley, MASSACHUSETTS
Growth
Filed SEC Form D on 20260813 for $7.1M Regulation D offering
Last Round
Form D filing — $7.12M (20260813)
Fundraising Status
Form D filing · $7.12M
privateTotal raised $7.12M
Latest Funding Round
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Form D filing | $7.12M | 20260813 | — | — |
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
1 active · 1 recruiting
Lead phase
Phase 1
most advanced registered study
Focus areas
Relapsed Acute Myeloid Leukemia (AML)
Refractory Acute Myeloid Leukemia (AML) · Relapsed/Refractory AML
Latest trial start
2025-05-01
Talent Signal
No public careers page or job board could be found for Auron Therapeutics as of 2026-09-17. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
BiotechForm DRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.